Good news for Protalix Biotherapeutics (PLX) once again! The company completed the submission of its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for taliglucerase alfa, which is meant for the treatment of Gaucher disease. It has been granted orphan-drug designation and fast-track status by the FDA to facilitate its development.

Taliglucerase alfa is currently being given to patients suffering from Gaucher disease in the US and the European Union under the Expanded Access Program and compassionate use protocol, respectively.

Earlier this month, the company entered into an agreement with Pfizer (PFE) related to the development and commercialization of this drug. As per the deal, Pfizer will have exclusive worldwide licensing rights to commercialize taliglucerase alfa while Protalix has retained its commercialization rights in Israel. Under the agreement, Pfizer will also retain 60% ownership of the drug’s revenue and expenses. Accordingly, the company will pay $60 million upfront to Protalix and up to $55 million in additional milestone payments.

Protalix is going ahead with its plan for the drug’s use in pediatric patients, as well. The company filed its proposed pediatric investigation plan to the pediatric committee of the European Medicines Agency (EMEA) for a clinical study of the drug in patients of 2 to 18 years of age. The filing of the plan triggers a milestone payment of $5 million from Pfizer as per the deal.

Gaucher disease is a rare inherited condition, caused by the deficiency of a particular enzyme. It damages the liver and bone marrow causing anemia, excessive bleeding and bruising, among other symptoms.

Competition in the Gaucher disease market is quite strong with the presence of drugs such as Cerezyme from Genzyme (GENZ) and Shire plc’s (SHPGY) velaglucerase alfa, which is currently available under the FDA’s expanded access program. However, we believe Protalix’s taliglucerase alfa to be a formidable competitor in the market, backed by Pfizer’s marketing muscle.

Zacks Investment Research

1. (GENZ) Genzyme Resumes Cerezyme ShipmentGenzyme Corp. (GENZ) recently reported progress on the resumption of supply of new lots of...
2. (SHPGY) Shire Plc’s Drug Seeks European Medicines Agency ApprovalShire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The...
3. (PLX) Protalix BioTherapeutics Wins Orphan Drug StatusYesterday, Protalix BioTherapeutics, Inc. (PLX) announced that the U.S. Food and Drug Administration (FDA) has...
4. (SHPGY) Shire Moving Up with Gaucher DrugYesterday, Shire plc (SHPGY) submitted its new drug application (NDA) for velaglucerase alfa, its enzyme...
5. (GENZ) Another Blow for GenzymeYesterday, Protalix BioTherapeutics Inc., a potential competitor for Genzyme Corp.’s (GENZ) lead product Cerezyme, announced that the...
6. (GENZ) Genzyme’s Problems Continue – Shire competing directly with Genzyme’s lead productGenzyme Corp. (GENZ) suffered a setback earlier this week when Shire Plc. (SHPGY) announced positive...

Search Posts by Tag: GENZ | Genzyme Corporation | PFE | Pfizer Inc. | PLX | Protalix BioTherapeutics Inc | Shire Limited | SHPGY | Biotechnology | Healthcare

RSS Feeds by Tag: GENZ | Genzyme Corporation | PFE | Pfizer Inc. | PLX | Protalix BioTherapeutics Inc | Shire Limited | SHPGY | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author